Futura Medical plc (FAMDF)
OTCMKTS · Delayed Price · Currency is USD
0.1500
+0.0600 (66.67%)
Jul 25, 2025, 4:00 PM EDT
Futura Medical Company Description
Futura Medical plc research, develops, and sells pharmaceutical and healthcare products for sexual health.
Its lead product is Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women.
The company operates in the United Kingdom, the European Union, the United States, and internationally.
Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
Futura Medical plc
| Country | United Kingdom |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | James Barder |
Contact Details
Address: Surrey Technology Centre Guildford, GU2 7YG United Kingdom | |
| Phone | 44 14 8368 5670 |
| Website | futuramedical.com |
Stock Details
| Ticker Symbol | FAMDF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB0033278473 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James Henry Barder | Chief Executive Officer and Executive Director |
| Angela Hildreth | Chief Operating Officer, Finance Director, Company Secretary and Executive Director |
| Kenneth William James | Head of Research & Development and Executive Director |
| Dr. William Duncan Potter BSc (Hons), MSc, Ph.D. | Chief Scientific Officer and Adviser to the Board |
| Graham Smith | Head of Alliance Partnerships and Supply |
| Kevin Langridge | Head of Quality |